Home » Posts tagged with » Oncology
Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies

Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies

Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been dosed in a phase 1 clinical trial in China for evaluating IBI315 for the treatment of advanced solid malignancies. IBI315, which has been co-developed by the companies, is a recombinant fully human bispecific antibody targeting programmed cell […]

Cancer immunotherapy company EpicentRx raises $35m in Series D round

EpicentRx, a cancer immunotherapy company based in California, has secured $35 million of capital through a Series D financing round to support the development of small molecule immunotherapy and its oncolytic viral platform. The oncology company used the services of Biotech Alliances International, a Silicon Valley based life-science focused investment bank to get the funding. […]

Continue reading …
Chinese biopharma company Akeso raises $150m for antibody drug discovery

Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas, has raised nearly $150 million through a Series D funding round. The investment in the clinical stage company was led by Loyal Valley Capital (LVC) and Sino Biopharmaceutical. The co-investors in the Series D round are healthcare […]

Continue reading …
Yuhan Pharmaceuticals to use Cyclica’s AI-driven drug discovery platform

Yuhan Pharmaceuticals has entered into a collaboration with Canadian biotechnology company Cyclica to use the latter’s artificial intelligence (AI) driven integrated drug discovery platform in two separate research and development (R&D) programs in oncology. The South Korean healthcare company said that it is looking to adopt innovative technologies to boost its drug development efforts. In […]

Continue reading …
MicroMedicine to introduce new white blood cell isolation technology at SITC annual conference

MicroMedicine, a US life sciences technology company, will launch Sorterra Cell Isolation System, a white blood cell isolation technology, at the 34th Society for Immunotherapy of Cancer (SITC) annual conference to be held from November 6-10 in National Harbour, Maryland. Sorterra Cell Isolation System will separate white blood cells from human peripheral blood preserving sample […]

Continue reading …
Amgen to take 20.5% stake in Chinese biotech company BeiGene for $2.7bn

US biopharma company Amgen has signed an all-cash deal to acquire a 20.5% stake in Chinese biotech company BeiGene for about $2.7 billion, as per the latest pharma acquisition news. The Beijing-based BeiGene is a research-based, oncology-focused biotechnology company, which is engaged in developing molecularly targeted and immuno-oncology drug candidates for cancer treatment. The transaction […]

Continue reading …
LIPAC Oncology takes NMIBC treatment TBC-1002 into phase 2 A trial

Investigational NMIBC treatment TBC-1002 : LIPAC Oncology said that it has wrapped up a phase 1 clinical trial of TBC-1002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and has now initiated a phase 2 A clinical trial. The US pharma company, which is a subsidiary of California-based TesoRx Pharma, said that the phase […]

Continue reading …
The Pritzker Organization invests in AI-driven Systems Oncology

Systems Oncology, which uses big data and AI to discover scientific insights into cancer biology, has secured an undisclosed investment from the Pritzker Family Business Interests advised by The Pritzker Organization (TPO) during the first closing of its Series B round. The new capital will be used for investing in discovery research and pre-clinical development […]

Continue reading …
Elicio raises $33m to advance lymph node-targeted immuno-therapies

US immuno-oncology company Elicio Therapeutics has raised $33 million through a Series B financing round to advance ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS), and other lymph node targeted immuno-therapies. Elicio Therapeutics said that it has established an international investor base which includes Clal Biotechnology Industries, Efung Capital, and Livzon Pharmaceutical Group. According to the […]

Continue reading …
Varian introduces Ethos therapy – AI-powered cancer care delivery solution

Ethos therapy Varian : Varian, a cancer care technologies developer, has introduced Ethos therapy, an artificial intelligence (AI)-powered personalized cancer care delivery system in radiation oncology, as per the latest medical device news. Ethos therapy, designed to deliver adaptive treatment in a typical 15-minute timeslot, will target the tumor, reduce dose to healthy tissue and […]

Continue reading …
Page 1 of 8123Next ›Last »